Anti-PD-1, and CapOx for the First-line Treatment of dMMR Positive Esophagogastric Cancer (AuspiCiOus)
Status:
Recruiting
Trial end date:
2029-11-04
Target enrollment:
Participant gender:
Summary
To investigate the effects of the combination of two chemotherapies followed by
immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in
the tumour microenvironment in patients with previously untreated metastatic or locally
advanced esophagogastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)